Analyzing the Future of Genomic Biomarkers Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Future CAGR of the Genomic Biomarkers Market, and How Will It Impact Industry Expansion?
The surge in the size of the genomic biomarkers market in recent times is prominent. It is predicted to escalate from a $7.42 billion value in 2024 to a worth of $8.72 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 17.4%. The notable growth during the historic period is partly due to the increased focus on numerous genetic testing exercises, intensifying instances of chronic illnesses, the rising importance attached to precision medicine initiatives, an expanding acceptance of companion diagnostics, and an enhanced count of patients affected by neurological diseases.
The market size for genomic biomarkers is projected to experience a significant expansion in the coming years. It is likely to escalate to $16.51 billion in 2029 with a compound annual growth rate (CAGR) of 17.3%. Factors such as the rise in ovarian and gastric cancer instances, increased understanding and utilization of genetic testing, the growing employment of genomic biomarkers in the detection and treatment of cancer, the surging number of cancer patients, and the expanding acceptance of companion diagnostics, are likely to propel this growth during the forecast period. Key trends for this period would be next-generation sequencing (NGS), amalgamation with other omics, advancements in genomic technology, innovative products, and sophisticated healthcare services.
What Strategic Factors Are Influencing the Accelerated Growth of the Genomic Biomarkers Market?
The surge in demand for personalized, or precision, medicine is anticipated to fuel the rise of the genomic biomarkers market. Personalized medicine is a healthcare tactic that customizes medical decisions and treatments to each patient’s unique attributes, with an emphasis on their genetic and genomic data. The rise in demand for this type of medicine is attributed to various factors, including the focus on patient-centered care, progress in genetic sequencing and analysis, a patient-focused approach, and utilizing electronic health records to capture and analyze patient information. Genomic biomarkers have a fundamental role in personalized medicine as they enable medical professionals to adapt treatments to a patient’s distinct genetic profile. This strategy, known as precision medicine, intends to heighten the efficacy of treatments and lessen side effects by acknowledging genetic variances among individuals. For example, in 2022, the Personalized Medicine Coalition, a professional membership organization based in the US, reported the approval of 12 novel customized medications which represented approximately 34% of all new treatments, marking a 34% increase from previous years. Consequently, the surging demand for personalized medicine promotes the expansion of the genomic biomarkers market.
Request Your Free Genomic Biomarkers Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=19485&type=smp
What Are the Top Market Players Propelling the Growth of the Genomic Biomarkers Industry?
Major companies operating in the genomic biomarkers market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Illumina Inc., PerkinElmer Inc., Almac Group, Azenta Inc., Novogene Corporation, Oxford Nanopore Technologies Ltd., Celerion, Quanterix Corporation, Bio-Rad Laboratories Inc., NantHealth Inc., Centogene N.V., Sophia Genetics SA, Envisagenics, Deep Genomics, Creative Diagnostics, Macrogen Inc., Guardant Health Inc., Sema4
What Are the Key Trends to Watch in the Genomic Biomarkers Market Over the Coming Years?
Leading firms in the genomic biomarkers market are honing in on the creation of novel products such as lung reagents. Featured in diagnostic tests, research, and medical procedures connected with the lungs, these substances expedite precision medicine through guiding treatment decisions that take into account the distinct genetic composition of a cancer. They are designed to pinpoint genetic mutations specific to lung cancer which are essential in directing targeted therapies and personalised treatment plans. Integral to this innovation is the employment of cutting-edge genomic technologies aimed to boost diagnostic precision. An exemplar of this is Biofidelity, a UK-based company with specialisation in the advancement of genomic assays and precision diagnostics. In December 2023, Biofidelity released their ASPYRE-Lung reagents in pursuit of enhancing detection and treatment strategies for lung cancer.
Pre-order Your Report for Quick and Easy Delivery!
https://www.thebusinessresearchcompany.com/report/genomic-biomarkers-global-market-report
Which Primary Segments of the Genomic Biomarkers Market Are Driving Growth and Industry Transformations?
The genomic biomarkersmarket covered in this report is segmented –
1) By Type: Predictive Biomarkers, Prognostic Biomarkers
2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications
3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility
4) By End-User: Hospitals, Diagnostic Centers, Other End User
Subsegments:
1) By Predictive Biomarkers: Drug Response Biomarkers, Companion Diagnostics Biomarkers, Pharmacodynamic Biomarkers, Predictive Genetic Markers for Disease Susceptibility
2) By Prognostic Biomarkers: Cancer Prognostic Biomarkers, Cardiovascular Disease Prognostic Biomarkers, Neurodegenerative Disease Prognostic Biomarkers, Infectious Disease Prognostic Biomarkers
What Regions Are Dominating the Genomic Biomarkers Market Growth?
North America was the largest region in the genomic biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Defining Aspects of the Genomic Biomarkers Market Landscape?
Genomic biomarkers are specific sequences or variations in DNA or RNA that provide information about a biological process, condition, or response to a particular treatment. These biomarkers are used in precision medicine to predict disease risk, diagnose conditions, monitor disease progression, or guide treatment decisions. Genomic biomarkers are crucial for personalized medicine, allowing healthcare providers to tailor treatments based on an individual’s genetic makeup, improving the effectiveness of therapies, and reducing the likelihood of adverse effects.
Browse Through More Similar Reports By The Business Research Company:
Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2024
Single-Cell Genome Sequencing Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/single-cell-genome-sequencing-global-market-report
Cardiac Biomarkers Testing Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-testing-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
